Brokerages forecast that Oxford Immunotec Global PLC (NASDAQ:OXFD) will announce earnings of ($0.33) per share for the current quarter, according to Zacks. Three analysts have issued estimates for Oxford Immunotec Global’s earnings. The lowest EPS estimate is ($0.43) and the highest is ($0.23). Oxford Immunotec Global posted earnings per share of ($0.22) during the same quarter last year, which suggests a negative year over year growth rate of 50%. The business is expected to report its next quarterly earnings report on Tuesday, February 27th.
According to Zacks, analysts expect that Oxford Immunotec Global will report full year earnings of ($2.11) per share for the current financial year, with EPS estimates ranging from ($2.22) to ($2.00). For the next year, analysts expect that the company will post earnings of ($1.02) per share, with EPS estimates ranging from ($1.25) to ($0.75). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that follow Oxford Immunotec Global.
Several analysts have issued reports on the company. Zacks Investment Research lowered Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research note on Saturday, November 4th. BTIG Research set a $21.00 price objective on Oxford Immunotec Global and gave the company a “buy” rating in a research note on Tuesday, October 31st. Robert W. Baird restated a “buy” rating and issued a $20.00 price objective on shares of Oxford Immunotec Global in a research note on Wednesday, November 1st. ValuEngine lowered Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research note on Tuesday, October 31st. Finally, Piper Jaffray Companies dropped their price objective on Oxford Immunotec Global from $26.00 to $19.00 and set an “overweight” rating on the stock in a research note on Tuesday, October 31st. Two equities research analysts have rated the stock with a sell rating and four have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $19.75.
Oxford Immunotec Global (NASDAQ:OXFD) traded down $0.01 on Thursday, reaching $14.88. The company had a trading volume of 181,137 shares, compared to its average volume of 162,600. Oxford Immunotec Global has a fifty-two week low of $12.19 and a fifty-two week high of $19.51. The company has a debt-to-equity ratio of 0.38, a quick ratio of 4.30 and a current ratio of 4.72.
In other Oxford Immunotec Global news, CEO Peter Wrighton-Smith sold 55,000 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $16.78, for a total value of $922,900.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Richard A. Sandberg sold 3,000 shares of the stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $13.35, for a total value of $40,050.00. Following the transaction, the director now owns 17,778 shares in the company, valued at approximately $237,336.30. The disclosure for this sale can be found here. 8.11% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Teachers Advisors LLC increased its stake in shares of Oxford Immunotec Global by 20.5% during the second quarter. Teachers Advisors LLC now owns 55,674 shares of the company’s stock worth $936,000 after purchasing an additional 9,474 shares during the period. Wasatch Advisors Inc. increased its stake in shares of Oxford Immunotec Global by 35.5% during the third quarter. Wasatch Advisors Inc. now owns 574,174 shares of the company’s stock worth $9,646,000 after purchasing an additional 150,343 shares during the period. Bank of New York Mellon Corp increased its stake in shares of Oxford Immunotec Global by 13.5% during the second quarter. Bank of New York Mellon Corp now owns 62,566 shares of the company’s stock worth $1,052,000 after purchasing an additional 7,435 shares during the period. Redmile Group LLC increased its stake in shares of Oxford Immunotec Global by 7.5% during the second quarter. Redmile Group LLC now owns 2,155,949 shares of the company’s stock worth $36,263,000 after purchasing an additional 151,100 shares during the period. Finally, Birchview Capital LP increased its stake in shares of Oxford Immunotec Global by 14.9% during the third quarter. Birchview Capital LP now owns 77,303 shares of the company’s stock worth $1,299,000 after purchasing an additional 10,000 shares during the period. Institutional investors own 89.35% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of US and international trademark and copyright legislation. The original version of this piece of content can be read at https://ledgergazette.com/2017/12/03/brokerages-expect-oxford-immunotec-global-plc-oxfd-to-post-0-33-eps.html.
About Oxford Immunotec Global
Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with MarketBeat.com's FREE daily email newsletter.